Board Decisions

GF/B19/DP18


Approved by the Board on:
06 May 2009


Quality Assurance Review of the Status of Pharmaceutical Products Other than anti-Retroviral, anti-Malaria and anti-Tuberculosis Medicines

The Board requests the Portfolio Committee (PC) to oversee the Secretariat's study of the quality assurance status of pharmaceutical products other than anti-retroviral, anti-malaria and anti-tuberculosis medicines. The Secretariat shall present the findings of the first phase of the study to the PC at its 12th Meeting in September 2009. Based on these findings, the PC may permit the Secretariat to undertake the later stages of the study to explore the possibility of establishing a quality assurance policy for these products. The Board requests the PC to update the Board on the progress of the study at the Board's first meeting in 2010.

Budgetary Implications

The budgetary implications of this decision are estimated at approximately US$ 250,000 in 2009 for consultations, meetings and professional fees. The Secretariat will endeavor to absorb the incremental costs in 2009 by making commensurate savings within the already approved budget.